Cassava Sciences | PTIE - Current Liabilities


Cassava Sciences reported $43.83M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Abbott USD 16.5B 1.91B Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
Cara Therapeutics USD 11.04M 362K Sep/2025
Cassava Sciences USD 43.83M 4.21M Dec/2025
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Geron USD 113.82M 26.11M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Novartis USD 27.28B 4.72B Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Roche Holding CHF 28B 421M Dec/2025